Ceftaroline fosamil: Difference between revisions
| Line 22: | Line 22: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]:B | ||
*Lactation: | *Lactation: Safety Unknown | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl 30-50: 400 mg q12h; CrCl 15-30: 300 mg q12h; ESRD/HD: 200 mg q12h | ||
**Pediatric | **Pediatric: Drug not available for pediatrics | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: No Adjustment | ||
**Pediatric | **Pediatric: NA | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 02:00, 17 May 2014
General
- Type: 5th Generation Cephalosporin
- Dosage Forms: IV
- Common Trade Names: Teflro
Adult Dosing
Community Acquired Pneumonia
- 600 mg IV q12h x5-7 days
Cellulitis
- 600 mg IV q12h x5-14 days
Renal Dosing
- CrCl 30-50: 400 mg q12h; CrCl 15-30: 300 mg q12h; ESRD/HD: 200 mg q12h
Hepatic Dosing
- No adjustment
Pediatric Dosing
- Currently no pediatric dosing for this drug.
Special Populations
- Pregnancy Rating:B
- Lactation: Safety Unknown
- Renal Dosing
- Adult: CrCl 30-50: 400 mg q12h; CrCl 15-30: 300 mg q12h; ESRD/HD: 200 mg q12h
- Pediatric: Drug not available for pediatrics
- Hepatic Dosing
- Adult: No Adjustment
- Pediatric: NA
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: